NASDAQ:ZBIO Zenas BioPharma (ZBIO) Stock Price, News & Analysis $30.86 -1.06 (-3.31%) As of 11:30 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Zenas BioPharma Stock (NASDAQ:ZBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zenas BioPharma alerts:Sign Up Key Stats Today's Range$30.48▼$32.0650-Day Range$27.68▼$33.7752-Week Range$13.50▼$44.60Volume122,315 shsAverage Volume817,622 shsMarket Capitalization$2.01 billionP/E RatioN/ADividend YieldN/APrice Target$45.71Consensus RatingModerate Buy Company Overview Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for patients with immune-mediated diseases. The company’s research and development efforts are centered on therapies that modulate the immune system and address conditions with significant unmet medical needs. Zenas’ lead investigational product is obexelimab, an immune-modulating monoclonal antibody designed to inhibit the activity of certain B cells without broadly depleting them. The company is evaluating obexelimab in autoimmune and inflammatory diseases, including IgG4-related disease and systemic lupus erythematosus. As an investigational therapy, obexelimab has not been approved for commercial use. The company advances its programs through clinical development and collaborations with biotechnology and pharmaceutical partners. Zenas BioPharma is headquartered in Waltham, Massachusetts, and its development activities are focused primarily on clinical trials in the United States and other international markets.AI Generated. May Contain Errors. Read More Zenas BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreZBIO MarketRank™: Zenas BioPharma scored higher than 43% of companies evaluated by MarketBeat, and ranked 639th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingZenas BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialZenas BioPharma has a consensus price target of $45.71, representing about 43.3% upside from its current price of $31.91.Amount of Analyst CoverageZenas BioPharma has only been the subject of 4 research reports in the past 90 days.Read more about Zenas BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Zenas BioPharma are expected to grow in the coming year, from ($5.81) to ($4.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zenas BioPharma is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zenas BioPharma is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZenas BioPharma has a P/B Ratio of 7.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zenas BioPharma's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.02% of the float of Zenas BioPharma has been sold short.Short Interest Ratio / Days to CoverZenas BioPharma has a short interest ratio ("days to cover") of 14.18, which indicates bearish sentiment.Change versus previous monthShort interest in Zenas BioPharma has recently increased by 0.37%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZenas BioPharma does not currently pay a dividend.Dividend GrowthZenas BioPharma does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.86 News SentimentZenas BioPharma has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Zenas BioPharma this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for ZBIO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Zenas BioPharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zenas BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.00% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsZenas BioPharma has minimal institutional ownership at this time.Read more about Zenas BioPharma's insider trading history. Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zenas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZBIO Stock News HeadlinesZenas BioPharma, Inc. (ZBIO)1 hour ago | finance.yahoo.comZenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14 at 10:00 PM | seekingalpha.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 15 at 1:00 AM | InvestorPlace (Ad)Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 9, 2026 | seekingalpha.comZenas BioPharma to Host Obexelimab IgG4-RD Investor EventSeptember 8, 2026 | globenewswire.comZenas BioPharma to Present at Upcoming Healthcare Investor ConferencesSeptember 4, 2026 | globenewswire.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 18, 2026 | globenewswire.comZenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 13, 2026 | globenewswire.comSee More Headlines ZBIO Stock Analysis - Frequently Asked Questions How have ZBIO shares performed this year? Zenas BioPharma's stock was trading at $36.31 at the beginning of the year. Since then, ZBIO shares have decreased by 12.1% and is now trading at $31.91. How were Zenas BioPharma's earnings last quarter? Zenas BioPharma, Inc. (NASDAQ:ZBIO) posted its earnings results on Wednesday, August, 12th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by $0.65. The company earned $1 million during the quarter, compared to the consensus estimate of $15 million. When did Zenas BioPharma IPO? Zenas BioPharma (ZBIO) raised $225 million in an IPO on Thursday, September 12th 2024. The company issued 13,235,294 shares at $16.00-$18.00 per share. Who are Zenas BioPharma's major shareholders? Top institutional investors of Zenas BioPharma include BlackRock Inc. (4.26%), Wellington Management Group LLP (2.45%), Bank of America Corp DE (1.89%) and California State Teachers Retirement System (1.15%). Insiders that own company stock include Fairmount Funds Management Llc, Sr One Capital Management, Llc, Jason Raleigh Nunn, Hongbo Lu, Leon O Moulder Jr, Patricia L Allen and Patrick G Enright. View institutional ownership trends. How do I buy shares of Zenas BioPharma? Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zenas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas BioPharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), Ford Motor (F) and Genius Sports (GENI). Company Calendar Last Earnings8/12/2026Today9/15/2026H.C. Wainwright 28th Annual Global Investment Conference9/16/2026Study update9/29/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ZBIO's financial health is in the Green zone, according to TradeSmith. ZBIO has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZBIO Previous SymbolNASDAQ:ZBIO CIK1953926 Webzenasbio.com Phone(857) 271-2954FaxN/AEmployees167Year Founded2019Price Target and Rating Average Price Target for Zenas BioPharma$45.71 High Price Target$55.00 Low Price Target$32.00 Potential Upside/Downside+48.2%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($8.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$377.74 million Net MarginsN/A Pretax Margin-48,416.40% Return on Equity-122.45% Return on Assets-58.04% Debt Debt-to-Equity Ratio1.57 Current Ratio9.93 Quick Ratio9.93 Sales & Book Value Annual Sales$10 million Price / Sales200.99 Cash FlowN/A Price / Cash FlowN/A Book Value$4.51 per share Price / Book6.84Miscellaneous Outstanding Shares65,180,000Free Float50,838,000Market Cap$2.01 billion OptionableN/A Beta-1.04 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 9/15/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThe IRA Mistake That Could Cost Americans 55+ Thousands in 2026JPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...Golden Crest Metals | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
